Remco de Vrueh currently works as senior advisor at Schuttelaar & Partners, a Dutch communications consultancy firm. Prior to this he worked for the Netherlands Organisation for Health Research and Development (largest Dutch health research funding agency) as advisor to various (orphan) drug and innovation programmes.
Between 2006 and 2011 he was active as Orphan Product Developer for the Dutch Steering Committee on Orphan Drugs. He was responsible for stimulating development of orphan drugs by the Dutch pharmaceutical industry. Apart from industry, he actively interacted with a.o. academia and patient organizations. He (co-)organized meetings, has given presentations, provided training and teaching, and is the (co-)author of several scientific publications. In the same period he also fulfilled interim project management positions for the European and Developing Countries Clinical Trials Partnership and the Dutch Medicines Evaluation Board. Before joining the Steering Committee he worked at OctoPlus, a Dutch pharmaceutical company. Remco de vrueh holds a PhD degree in Biopharmaceutical Sciences from the Leiden-Amsterdam Center for Drug Research in the Netherlands.
